4 results
This non-controlled multicentric phase II study is designed to assess the safety and to describe (in relation to children of higher age) the pharmacodynamics of recombinant ASNase for first-line treatment of infants (< 1 year of age at…
Primary Objective:To evaluate the duration of clinical response of ruxolitinib cream in participants with vitiligo.
Primary:To evaluate the efficacy of ruxolitinib cream in participants with vitiligo.Secondary:To further assess the efficacy of ruxolitinib cream.To evaluate the safety and tolerability of ruxolitinib cream.To evaluate the ruxolitinib PK in plasma…
This multicentre phase III study is designed to assess the efficacy and safety of recombinant versus E-Coli derived Aaparaginase from Medac, during treatment of children with newly diagnosed ALL according to the DCOG ALL-10 protocol.Futhermore: To…